These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 37225974)

  • 21. [Cross-validation of Quantitative Analytical Software Using 18F-florbetapir PET Imaging].
    Wagatsuma K; Miwa K; Sakata M; Ishibashi K; Ishii K
    Nihon Hoshasen Gijutsu Gakkai Zasshi; 2021; 77(1):32-40. PubMed ID: 33473077
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantification of amyloid PET for future clinical use: a state-of-the-art review.
    Pemberton HG; Collij LE; Heeman F; Bollack A; Shekari M; Salvadó G; Alves IL; Garcia DV; Battle M; Buckley C; Stephens AW; Bullich S; Garibotto V; Barkhof F; Gispert JD; Farrar G;
    Eur J Nucl Med Mol Imaging; 2022 Aug; 49(10):3508-3528. PubMed ID: 35389071
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Longitudinal Assessment of Amyloid-β Deposition by [18F]-Flutemetamol PET Imaging Compared With [11C]-PIB Across the Spectrum of Alzheimer's Disease.
    Hatashita S; Wakebe D; Kikuchi Y; Ichijo A
    Front Aging Neurosci; 2019; 11():251. PubMed ID: 31572167
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease.
    Leuzy A; Smith R; Cullen NC; Strandberg O; Vogel JW; Binette AP; Borroni E; Janelidze S; Ohlsson T; Jögi J; Ossenkoppele R; Palmqvist S; Mattsson-Carlgren N; Klein G; Stomrud E; Hansson O
    JAMA Neurol; 2022 Feb; 79(2):149-158. PubMed ID: 34928318
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of Standardized Uptake Value Ratio Calculations in Amyloid Positron Emission Tomography Brain Imaging.
    Knešaurek K; Warnock G; Kostakoglu L; Burger C;
    World J Nucl Med; 2018; 17(1):21-26. PubMed ID: 29398961
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Centiloid scaling for quantification of brain amyloid with [
    Battle MR; Pillay LC; Lowe VJ; Knopman D; Kemp B; Rowe CC; Doré V; Villemagne VL; Buckley CJ
    EJNMMI Res; 2018 Dec; 8(1):107. PubMed ID: 30519791
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [(18)F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid β detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies.
    Rinne JO; Wong DF; Wolk DA; Leinonen V; Arnold SE; Buckley C; Smith A; McLain R; Sherwin PF; Farrar G; Kailajärvi M; Grachev ID
    Acta Neuropathol; 2012 Dec; 124(6):833-45. PubMed ID: 23053137
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Software development for quantitative analysis of brain amyloid PET.
    Matsuda H; Yamao T
    Brain Behav; 2022 Mar; 12(3):e2499. PubMed ID: 35134278
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of Tracer Retention Levels on Visual Analysis of Cerebral [
    Giovacchini G; Giovannini E; Borsò E; Lazzeri P; Duce V; Ferrando O; Foppiano F; Ciarmiello A
    Curr Radiopharm; 2021; 14(1):70-77. PubMed ID: 32727344
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Defining a Centiloid scale threshold predicting long-term progression to dementia in patients attending the memory clinic: an [
    Hanseeuw BJ; Malotaux V; Dricot L; Quenon L; Sznajer Y; Cerman J; Woodard JL; Buckley C; Farrar G; Ivanoiu A; Lhommel R
    Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):302-310. PubMed ID: 32601802
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression of regional brain amyloid-β deposition with
    Bao YW; Wang ZJ; Guo LL; Bai GJ; Feng Y; Zhao GD
    Neuroradiology; 2024 Apr; ():. PubMed ID: 38676749
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimal Reference Region to Measure Longitudinal Amyloid-β Change with
    Bullich S; Villemagne VL; Catafau AM; Jovalekic A; Koglin N; Rowe CC; De Santi S
    J Nucl Med; 2017 Aug; 58(8):1300-1306. PubMed ID: 28183994
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Image reconstruction methods affect software-aided assessment of pathologies of [
    Lindström E; Oddstig J; Danfors T; Jögi J; Hansson O; Lubberink M
    Neuroimage Clin; 2020; 28():102386. PubMed ID: 32882645
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An in vivo evaluation of cerebral cortical amyloid with [18F]flutemetamol using positron emission tomography compared with parietal biopsy samples in living normal pressure hydrocephalus patients.
    Wong DF; Moghekar AR; Rigamonti D; Brašić JR; Rousset O; Willis W; Buckley C; Smith A; Gok B; Sherwin P; Grachev ID
    Mol Imaging Biol; 2013 Apr; 15(2):230-7. PubMed ID: 22878921
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Improved beta-amyloid PET reproducibility using two-phase acquisition and grey matter delineation.
    Belohlavek O; Jaruskova M; Skopalova M; Szarazova G; Simonova K
    Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):297-303. PubMed ID: 30159586
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of Flutemetamol F 18-Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnestic Mild Cognitive Impairment.
    Wolk DA; Sadowsky C; Safirstein B; Rinne JO; Duara R; Perry R; Agronin M; Gamez J; Shi J; Ivanoiu A; Minthon L; Walker Z; Hasselbalch S; Holmes C; Sabbagh M; Albert M; Fleisher A; Loughlin P; Triau E; Frey K; Høgh P; Bozoki A; Bullock R; Salmon E; Farrar G; Buckley CJ; Zanette M; Sherwin PF; Cherubini A; Inglis F
    JAMA Neurol; 2018 Sep; 75(9):1114-1123. PubMed ID: 29799984
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    Chang Y; Li C; Yang H; Wu Y; Xu B; Zhang J; Wang R
    Front Neurosci; 2020; 14():745. PubMed ID: 32848542
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: a cross-validation study against amyloid positron emission tomography.
    Palmqvist S; Zetterberg H; Blennow K; Vestberg S; Andreasson U; Brooks DJ; Owenius R; Hägerström D; Wollmer P; Minthon L; Hansson O
    JAMA Neurol; 2014 Oct; 71(10):1282-9. PubMed ID: 25155658
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [(18)F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer's disease: specific detection of advanced phases of amyloid-β pathology.
    Thal DR; Beach TG; Zanette M; Heurling K; Chakrabarty A; Ismail A; Smith AP; Buckley C
    Alzheimers Dement; 2015 Aug; 11(8):975-85. PubMed ID: 26141264
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Validation of amyloid PET positivity thresholds in centiloids: a multisite PET study approach.
    Royse SK; Minhas DS; Lopresti BJ; Murphy A; Ward T; Koeppe RA; Bullich S; DeSanti S; Jagust WJ; Landau SM;
    Alzheimers Res Ther; 2021 May; 13(1):99. PubMed ID: 33971965
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.